Trimethoprim-associated hyperkalaemia: a systematic review and meta-analysis.

Details

Serval ID
serval:BIB_CA717CF8E14D
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Trimethoprim-associated hyperkalaemia: a systematic review and meta-analysis.
Journal
The Journal of antimicrobial chemotherapy
Author(s)
Faré P.B., Memoli E., Treglia G., Bianchetti M.G., Milani G.P., Marchisio P., Lava SAG, Janett S.
ISSN
1460-2091 (Electronic)
ISSN-L
0305-7453
Publication state
Published
Issued date
30/09/2022
Peer-reviewed
Oui
Volume
77
Number
10
Pages
2588-2595
Language
english
Notes
Publication types: Journal Article ; Meta-Analysis ; Systematic Review ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Abstract
Trimethoprim is structurally similar to potassium-sparing diuretics and may induce hyperkalaemia. The prevalence and the factors that predispose to trimethoprim-associated hyperkalaemia have never been extensively addressed.
A literature search with no date or language limits was carried out using the National Library of Medicine, Embase and Web of Science in March and repeated during August 2021. The principles underlying the Economic and Social Research Council guidance on the conduct of synthesis and the PRISMA guidelines were employed. For the analysis, we retained reports including ≥10 subjects on treatment with trimethoprim, which addressed the possible occurrence of hyperkalaemia.
Eighteen reports were retained for the final analysis. The pooled prevalence of potassium value >5.0 mmol/L, >5.5 mmol/L and >6.0 mmol/L or symptomatic, was, respectively, 22%, 10% and 0.2%. The analysis disclosed that the risk of trimethoprim-associated hyperkalaemia is dose-related and enhanced by drugs with known hyperkalaemic potential including potassium-sparing diuretics, renin-angiotensin-aldosterone system inhibitors, β-blockers and non-steroidal anti-inflammatory agents. Poor kidney function also increased the tendency towards hyperkalaemia. The time to onset of hyperkalaemia was generally 1 week or less after starting trimethoprim.
The present analysis documents the hyperkalaemic potential of trimethoprim, a widely prescribed drug that was introduced more than 50 years ago. Clinicians must recognize patients at risk of trimethoprim-associated hyperkalaemia.
Keywords
Anti-Inflammatory Agents, Non-Steroidal, Diuretics, Humans, Hyperkalemia/chemically induced, Hyperkalemia/epidemiology, Hyperkalemia/therapy, Potassium, Trimethoprim/adverse effects, United States
Pubmed
Web of science
Create date
06/09/2022 10:25
Last modification date
21/11/2023 7:09
Usage data